---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-023837"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:49:17.832945+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Graphite Bio doses first patient with nula-cel; Q3 net loss $24.7M; cash runway into Q4 2024

## Summary
- Dosed first sickle cell patient with nula-cel; initial proof-of-concept data on track for mid-2023.
- Q3 net loss $24.7M ($0.45 per share); R&D expenses $18.3M, G&A $7.9M.
- Cash, equivalents and investments $305.1M as of Sep 30, 2022; runway into Q4 2024.
- Entered strategic manufacturing partnership with WuXi Advanced Therapies for nula-cel.
- Two abstracts accepted for ASH 2022; hired Darren Hart as SVP of development.

## SEC filing metadata
- accession: 0000950170-22-023837
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000095017022023837/0000950170-22-023837-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000095017022023837/grph-20221109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-023837
- JSON: https://secwatch.observer/filing/0000950170-22-023837.json
- Plain text: https://secwatch.observer/filing/0000950170-22-023837.txt

## Key facts
- Earnings Releases
  LENZ Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income Net loss was $24.7 million, or $0.45 per basic and diluted share, EPS $0.45 per basic and diluted share.
  - Period: the quarter ended September 30, 2022
  - Net income: Net loss was $24.7 million, or $0.45 per basic and diluted share
  - EPS: $0.45 per basic and diluted share
  - Result: reported results
  source text: Graphite Bio, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815776/000095017022023837/0000950170-22-023837-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.